SOURCE: SRI International

November 02, 2007 13:16 ET

Steven Samuelsson Joins SRI International's Biosciences Division as Director of Imaging

MENLO PARK, CA--(Marketwire - November 2, 2007) - SRI International, an independent nonprofit research and development organization, announced today that Steven Samuelsson, Ph.D., has joined SRI's Biosciences Division as director of imaging. He will lead efforts in microscopy and imaging-based assays for drug discovery and development.

SRI's molecular morphology researchers provide clients and partners with imaging solutions that include light and electron microscopy, histology, immunolabeling, and image analysis. This function is integral to programs in cancer biology, infectious disease, ophthalmics, muscle biology and neuroscience. Laboratories are equipped with instrumentation for cell biological and biophysical studies into biological activities of drugs and medical devices.

Samuelsson joins SRI from (OSI) Eyetech Pharmaceuticals, Inc., where he was associate director of experimental pathology. In that role, he provided imaging expertise in anti-angiogenesis studies for drug discovery and delivery programs.

"Dr. Samuelsson is an experienced imaging scientist who brings valuable technical and leadership skills to SRI's molecular morphology group," said Nathan Collins, Ph.D., executive director of drug discovery in SRI's Biosciences Division. "He is a strong addition to our collaborative capabilities."

Prior to (OSI) Eyetech Pharmaceuticals, Dr. Samuelsson was a senior scientist at Procter & Gamble Pharmaceuticals, where he led the Cell and Molecular Imaging Group. He was a member of bone, muscle, and vascular biology teams within the company.

He received his B.S. degree in biochemistry/nutritional science from the University of California, Berkeley and his Ph.D. in membrane biology from the department of physiology at the University of Maryland School of Medicine, Baltimore.

About SRI's Biosciences Division

SRI International's Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials -- and specializes in cancer, immunology, infectious disease, and neuroscience research. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.

Contact Information